niacinamide has been researched along with Keratoacanthoma in 11 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
Keratoacanthoma: A benign, non-neoplastic, usually self-limiting epithelial lesion closely resembling squamous cell carcinoma clinically and histopathologically. It occurs in solitary, multiple, and eruptive forms. The solitary and multiple forms occur on sunlight exposed areas and are identical histologically; they affect primarily white males. The eruptive form usually involves both sexes and appears as a generalized papular eruption.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We report a 63-year-old Caucasian male who developed multiple cutaneous eruptive keratoacanthomas after starting sorafenib 400 mg twice daily." | 8.02 | Sorafenib-related generalized eruptive keratoacanthomas (Grzybowski syndrome): a case report. ( Abbas, MN; Kichenadasse, G; Tan, WS, 2021) |
| "These data suggest that there could be an association between sorafenib therapy and the development of cutaneous SCC and inflammation of AK." | 7.75 | Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib. ( Dubauskas, Z; Hwu, P; Jonasch, E; Kunishige, J; Prieto, VG; Tannir, NM, 2009) |
| "To report the development of keratoacanthoma (KA)-type squamous cell carcinomas (SCCs) in patients treated with the multikinase inhibitor sorafenib for the treatment of solid tumors, to present the possible mechanisms for induction of these SCCs, and to discuss the implications for discontinuation of therapy and possible cotherapies to decrease this side effect." | 7.75 | Eruptive keratoacanthoma-type squamous cell carcinomas in patients taking sorafenib for the treatment of solid tumors. ( Haley, H; Hamza, S; Skelton, HG; Smith, KJ, 2009) |
| "Sorafenib is a multikinase inhibitor that displays antiproliferative and antiangiogenic properties in the treatment of solid tumors." | 5.37 | Eruptive squamous cell carcinomas with keratoacanthoma-like features in a patient treated with sorafenib. ( Adams, DR; Lynch, MC; Straub, R, 2011) |
| "Sorafenib has been approved for use in the treatment of metastatic renal cell carcinoma." | 5.35 | [Sorafenib-induced multiple eruptive keratoacanthomas]. ( Dupre-Goetghebeur, D; Jantzem, H; Merrer, J; Spindler, P, 2009) |
| "We report a 63-year-old Caucasian male who developed multiple cutaneous eruptive keratoacanthomas after starting sorafenib 400 mg twice daily." | 4.02 | Sorafenib-related generalized eruptive keratoacanthomas (Grzybowski syndrome): a case report. ( Abbas, MN; Kichenadasse, G; Tan, WS, 2021) |
| "These data suggest that there could be an association between sorafenib therapy and the development of cutaneous SCC and inflammation of AK." | 3.75 | Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib. ( Dubauskas, Z; Hwu, P; Jonasch, E; Kunishige, J; Prieto, VG; Tannir, NM, 2009) |
| "To report the development of keratoacanthoma (KA)-type squamous cell carcinomas (SCCs) in patients treated with the multikinase inhibitor sorafenib for the treatment of solid tumors, to present the possible mechanisms for induction of these SCCs, and to discuss the implications for discontinuation of therapy and possible cotherapies to decrease this side effect." | 3.75 | Eruptive keratoacanthoma-type squamous cell carcinomas in patients taking sorafenib for the treatment of solid tumors. ( Haley, H; Hamza, S; Skelton, HG; Smith, KJ, 2009) |
| "Cutaneous adverse events commonly reported with tyrosine kinase inhibitors (TKIs) in the treatment of malignancies, represent an important clinical concern since they can limit the optimal use of these novel drugs." | 2.48 | Early detection, prevention and management of cutaneous adverse events due to sorafenib: recommendations from the Sorafenib Working Group. ( Bracarda, S; Cortesi, E; D'Angelo, A; Ferraù, F; Merlano, M; Monti, M; Ruggeri, EM; Santoro, A, 2012) |
| "Sorafenib is a multikinase inhibitor that displays antiproliferative and antiangiogenic properties in the treatment of solid tumors." | 1.37 | Eruptive squamous cell carcinomas with keratoacanthoma-like features in a patient treated with sorafenib. ( Adams, DR; Lynch, MC; Straub, R, 2011) |
| "Sorafenib has been approved for use in the treatment of metastatic renal cell carcinoma." | 1.35 | [Sorafenib-induced multiple eruptive keratoacanthomas]. ( Dupre-Goetghebeur, D; Jantzem, H; Merrer, J; Spindler, P, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (54.55) | 29.6817 |
| 2010's | 3 (27.27) | 24.3611 |
| 2020's | 2 (18.18) | 2.80 |
| Authors | Studies |
|---|---|
| Abbas, MN | 1 |
| Tan, WS | 1 |
| Kichenadasse, G | 1 |
| Blomberg, M | 1 |
| He, SY | 1 |
| Harwood, C | 1 |
| Arron, ST | 1 |
| Demehri, S | 1 |
| Green, A | 1 |
| Asgari, MM | 1 |
| Marka, A | 1 |
| Hoyt, BS | 1 |
| Linos, K | 1 |
| Vidal, NY | 1 |
| Marquez, CB | 1 |
| Smithberger, EE | 1 |
| Bair, SM | 1 |
| Wenham, RM | 1 |
| Fenske, NA | 1 |
| Glass, LF | 1 |
| Cherpelis, BS | 1 |
| Dubauskas, Z | 1 |
| Kunishige, J | 1 |
| Prieto, VG | 1 |
| Jonasch, E | 1 |
| Hwu, P | 1 |
| Tannir, NM | 1 |
| Arnault, JP | 1 |
| Wechsler, J | 1 |
| Escudier, B | 1 |
| Spatz, A | 1 |
| Tomasic, G | 1 |
| Sibaud, V | 1 |
| Aractingi, S | 1 |
| Grange, JD | 1 |
| Poirier-Colame, V | 1 |
| Malka, D | 1 |
| Soria, JC | 1 |
| Mateus, C | 1 |
| Robert, C | 1 |
| Smith, KJ | 1 |
| Haley, H | 1 |
| Hamza, S | 1 |
| Skelton, HG | 1 |
| Jantzem, H | 1 |
| Dupre-Goetghebeur, D | 1 |
| Spindler, P | 1 |
| Merrer, J | 1 |
| Lynch, MC | 1 |
| Straub, R | 1 |
| Adams, DR | 1 |
| Bracarda, S | 1 |
| Ruggeri, EM | 1 |
| Monti, M | 1 |
| Merlano, M | 1 |
| D'Angelo, A | 1 |
| Ferraù, F | 1 |
| Cortesi, E | 1 |
| Santoro, A | 1 |
| Kong, HH | 1 |
| Cowen, EW | 1 |
| Azad, NS | 1 |
| Dahut, W | 1 |
| Gutierrez, M | 1 |
| Turner, ML | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Study of BAY 43-9006 (Sorafenib) in Metastatic, Androgen-Independent Prostate Cancer[NCT00090545] | Phase 2 | 46 participants (Actual) | Interventional | 2004-09-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Geometric mean exposure for sorafenib. (NCT00090545)
Timeframe: 0, 0.25, 0.50, 1, 2, 4, 6, 8, 12, and 24 hours post-dose
| Intervention | mg/L.h (Geometric Mean) |
|---|---|
| First Stage - Disease Progression | 9.76 |
| Second Stage - Increased Accrual | 18.63 |
Plasma concentration-time profile for sorafenib. (NCT00090545)
Timeframe: 0, 0.25, 0.50, 1, 2, 4, 6, 8, 12, AND 24 hours post dose
| Intervention | mg/L (Mean) |
|---|---|
| First Stage - Disease Progression | 1.28 |
| Second Stage - Increased Accrual | 2.57 |
Time from treatment start date until date of death or date last known alive. (NCT00090545)
Timeframe: Time from treatment start date until date of death or date last known alive, approximately 18.3 months.
| Intervention | Months (Median) |
|---|---|
| First Stage - Disease Progression | 18 |
| Second Stage - Increased Accrual | 18.3 |
Here is the number of participants with adverse events. For the detailed list of adverse events, see the adverse event module. (NCT00090545)
Timeframe: Date treatment consent signed to date off study, approximately 49 months.
| Intervention | Participants (Count of Participants) |
|---|---|
| First Stage - Disease Progression | 22 |
| Second Stage - Increased Accrual | 23 |
Determine whether BAY 43-9006 when used to treat metastatic prostate cancer is associated with having 50% of Patients Progression Free at 4 Months by clinical, radiographic, and prostatic specific antigen (PSA)criteria. (NCT00090545)
Timeframe: 4 months
| Intervention | months (Median) |
|---|---|
| First Stage - Disease Progression | 1.83 |
| Second Stage - Increased Accrual | 3.7 |
Time to maximum concentration for sorafenib. (NCT00090545)
Timeframe: 0, 0.25, 0.50, 1, 2, 4, 6, 8, 12, and 24 hours post-dose
| Intervention | hours (Median) |
|---|---|
| First Stage - Disease Progression | 0.68 |
| Second Stage - Increased Accrual | 8 |
Overall response was evaluated by the RECIST. Complete Response (CR) is the disappearance of all target lesions. Partial Response (PR) is at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD) is at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. Stable Disease (SD) is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. (NCT00090545)
Timeframe: Every 2 cycles (1 cycle = 28 days)
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Complete Response | Partial Response | Progressive Disease | Stable Disease | |
| First Stage - Disease Progression | 0 | 0 | 8 | 0 |
| Second Stage - Increased Accrual | 0 | 1 | 13 | 10 |
2 reviews available for niacinamide and Keratoacanthoma
| Article | Year |
|---|---|
Research gaps in the management and prevention of cutaneous squamous cell carcinoma in organ transplant recipients.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Squamous Cell; Health Behavior; Humans; Im | 2017 |
Early detection, prevention and management of cutaneous adverse events due to sorafenib: recommendations from the Sorafenib Working Group.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Disease M | 2012 |
9 other studies available for niacinamide and Keratoacanthoma
| Article | Year |
|---|---|
Sorafenib-related generalized eruptive keratoacanthomas (Grzybowski syndrome): a case report.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Exanthema; Humans; Keratoacanthoma; Male; Middle Ag | 2021 |
Eruptive Keratoacanthomas of the Upper Extremities Successfully Treated With Intralesional Corticosteroid After Multiple Treatment Failures.
Topics: Acitretin; Administration, Oral; Biopsy; Drug Resistance; Female; Fluorouracil; Forearm; Glucocortic | 2020 |
Multiple keratoacanthomas arising in the setting of sorafenib therapy: novel chemoprophylaxis with bexarotene.
Topics: Adenocarcinoma, Papillary; Anticarcinogenic Agents; Antineoplastic Agents; Antineoplastic Combined C | 2009 |
Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib.
Topics: Aged; Benzenesulfonates; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Drug Eruptions; Female; Hu | 2009 |
Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Squamous Cell; | 2009 |
Eruptive keratoacanthoma-type squamous cell carcinomas in patients taking sorafenib for the treatment of solid tumors.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Squamous Cell; Female; Humans; Keratoaca | 2009 |
[Sorafenib-induced multiple eruptive keratoacanthomas].
Topics: Adenocarcinoma; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Immunosuppr | 2009 |
Eruptive squamous cell carcinomas with keratoacanthoma-like features in a patient treated with sorafenib.
Topics: Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, S | 2011 |
Keratoacanthomas associated with sorafenib therapy.
Topics: Aged; Antineoplastic Agents; Arm; Benzenesulfonates; Facial Dermatoses; Female; Humans; Keratoacanth | 2007 |